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Statement of Translational Relevance 
This manuscript presents an evaluation of the radiological imaging of the HERBY study, 
which is combined with molecular and pathological tumor characterization. This represents a 
more detailed post-hoc analysis than undertaken in the recently published results of the 
primary study endpoints: safety and event free survival. In depth assessment of the 
heterogeneous nature of pediatric HGG employing all three modalities underlines the 
importance of anatomical localization, surgical resectability, chemo-radiotherapeutic response 
prediction and stratification, incidence of leptomeningeal (and subependymal) dissemination 
and pseudoprogression. Distinctive imaging features of diffuse midline gliomas associated 
with H3 K27M mutations are described and contrasted with other midline and cerebral 
hemispheric pediatric HGGs. This study provides important information to help define 






Background: The HERBY trial evaluated the benefit of the addition of the antiangiogenic 
agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients 
with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here 
aims to correlate imaging characteristics and outcome measures with pathological and 
molecular data. 
Methods: Radiological, pathological and molecular data were correlated with trial clinical 
information to retrospectively re-evaluate event free and overall survival. 
Results: One-hundred thirteen patients were randomized to the RT/TMZ arm (n =54) or the 
RT/TMZ+BEV (BEV arm; n =59). The tumor arose in the cerebral hemispheres in 68 patients 
(Cerebral group) and a midline location in 45 cases (Midline group). Pathological diagnosis 
was available in all cases and molecular data in 86/113. H3 K27M histone mutations were 
present in 23/32 Midline cases and H3 G34R/V mutations in 7/54 Cerebral cases. 
Total/near-total resection occurred in 44/68 (65%) Cerebral cases but only 5/45 (11%) 
Midline cases (p <0.05). Leptomeningeal metastases (27 cases, 13 with subependymal spread) 
at relapse were more frequent in Midline (17/45) than Cerebral tumors (10/68, p <0.05). Mean 
OS (14.1 months) and EFS (9.0 months) in Midline tumors were significantly lower than 
mean OS (20.7 months) and EFS (14.9 months) in Cerebral tumors (p <0.05). 
Pseudoprogression occurred in 8/111 (6.2%) cases.  
Conclusions: This study has shown that the poor outcome of midline tumors (compared to 
cerebral) may be related to 1) lesser surgical resection, 2) H3 K27M histone mutations, and 3) 













The HERBY trial was a phase II, open-label, randomized, multicenter study comparing the 
benefit of adding the antiangiogenic agent Bevacizumab (BEV arm) to conventional 
radiotherapy (RT) and Temozolomide (TMZ) (RT/TMZ arm) in children between 3 and 18 
years of age presenting with newly diagnosed, non-brainstem high-grade gliomas (HGG). 
Patients were recruited from 51 sites in 14 countries. The primary measures of response were 
overall survival (OS) and event free survival (EFS) after 12 months; the study outcomes were 




HGGs are one of the most common malignant primary neoplasms of the pediatric 
central nervous system (CNS), occurring with a frequency of approximately 0.85 per 
100,000
2
. These tumors were thought to be similar to HGG occurring in adults, however 
molecular, genetic and biological data now show that they are phenotypically distinct 
neoplasms
3
. Greater understanding of their biology offers the potential for a more tailored 
approach to treatment, particularly employing novel therapeutic techniques targeting 
molecular and genetic pathways. 
The need for expert neuropathological review within the context of a multicenter study 
is highlighted by the increasing understanding of the role played by the central midline 
location of a subset of pediatric HGG’s
4
. 
The imaging appearances of HGG are best evaluated by Magnetic Resonance Imaging 
(MRI), which most accurately defines the anatomical localization, tumor margins, 
enhancement characteristics and associated mass effect. Advanced MR imaging techniques 
offer the potential for a more ‘biological’ non-invasive evaluation of these tumors; diffusion 
weighted imaging (DWI) provides information regarding cellular density whilst perfusion 
weighted imaging (PWI) techniques enable assessment of tumor angiogenesis and capillary 
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permeability. The metabolic profile of these tumors is also increasingly evaluated using 
magnetic resonance spectroscopy (MRS)
5,6
. Whilst still regarded as investigational tools, 
these techniques are increasingly used in routine clinical practice. 
Long-term survival in children with these tumors remains poor; median survival in 
studies ranges from 9-15 months
7
. Recent progress in this field has been directed towards 
increasing recognition of the biological diversity of these tumors, their molecular profiling 
and differential response to therapeutic interventions reflecting tumor subsets ranging from 
more benign phenotypes resembling low-grade gliomas to highly aggressive lesions with 
bleak outcomes, such as seen in diffuse intrinsic pontine gliomas
4,8–10
. Imaging remains an 
integral component in the diagnosis and characterization of these tumors as well as 
monitoring the response to a range of therapeutic interventions employed in their treatment. 
The primary outcome measures (EFS and OS) of the study were evaluated using 
standard structural and multimodal MR imaging (MMI) techniques. Combining imaging with 
the main molecular genetic and consensus histopathological evaluations offers the potential to 
improve and enhance the management of these tumors, and formed the basis for the secondary 
research aims of the HERBY trial. Initial work to address this combination has recently been 
published with the focus on the molecular analysis
11
. This work expands on the radiological 
characterizations of the patients, focusing on: 
 Retrospective re-evaluation of and identification of additional radiological markers. 
 Pre-operative radiological characterizations correlated with molecular genetics and 
histopathology. 
 Evolution of radiological characteristics related to response, correlated with the baseline 




Materials and Methods 
The HERBY trial was conducted as part of a pediatric investigation plan. The protocol was 
approved by the applicable independent ethics committees and institutional review boards, 
and the study was conducted in accordance with applicable regulations, International Council 
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good 
Clinical Practice guidelines, and the ethical principles enshrined in the Declaration of 
Helsinki. Written informed consent was obtained from the patient/parents or legally 
acceptable representatives prior to enrolment; consent was also obtained prior to collection of 
tissue for the exploratory biomarker analyses. 
This paper addresses the initial Intention-To-Treat (ITT) cohort (n =121) of patients 
aged between 3 and 18 years who entered the HERBY trial between October 2011 and 
February 2015. All patients underwent expert Neuropathological consensus review prior to 
entering the trial. Exclusion criteria included: metastatic disease at study entry, previously 
treated HGG, diffuse tumors such as gliomatosis cerebri, tumors arising centrally within the 
pons, anaplastic ganglioglioma and pleomorphic xanthoastrocytoma.  
 
Imaging 
Radiological imaging was undertaken on all patients pre-operatively. In some cases from 
secondary sites, pre-operative imaging was not available for analysis and but some imaging 
characteristics (tumor site epicenter, lesion definition and degree or absence of perilesional 
edema) could still be derived from the immediate and early post-operative imaging. All post-
operative imaging was undertaken according to the previously published imaging protocol
12
. 
Tumor response evaluation was undertaken according to the Response Assessment in Neuro-
Oncology (RANO) criteria
13






To add value to the RANO evaluation required by the HERBY trial, post-hoc radiological 
analysis was undertaken to evaluate additional pre-operative MRI characteristics that were not 
predicated in the main HERBY assessment: epicenter location, necrosis/cysts, hemorrhage, 
tumor margin definition (well defined, ill-defined, or ill-defined-multifocal), contrast 
enhancement characteristics (strong, strong-focal, moderate, minor, none) and perilesional 
edema (severe, moderate, minor, none). Pre-operative tumor volumes and Apparent Diffusion 
Coefficient (ADC) values were also analyzed. Extent of resection was assessed according to a 
simplified version of the Vasari criteria
15
 (Total or near total tumor resection, >95%; major 
debulking, >50% and < 95%; minor debulking, <50% resection; biopsy). In patients with non 
or minimally enhancing tumor, extent of resection was determined by the absence of tissue on 
the pre-operative imaging that was identifiable as most likely to be tumoral on the basis of all 
imaging sequences available. In addition, the following post-operative measures were 
recorded: presence/absence and location of any leptomeningeal (or subependymal) metastatic 
(LMM) dissemination, pseudoprogression or pseudoresponse (psPD/psPR). For a more 




All patients in the main HERBY trial underwent a real-time pre-randomized screening by a 
central neuropathologist employing; post-hoc analysis of the tumor histology was undertaken 
by 6 experienced Neuropathologists, with reference to 2007 WHO classification
1
. Due to the 
newly defined entity diffuse midline glioma (DMG) grade IV, H3F3A K27M-mutant, 
introduced in the WHO 2016
16
  classification, the WHO 2007 grade was updated based on the 
combined presence of H3F3A  K27M mutation and midline location defined by imaging (i.e., 
midline-located, H3F3A  K27M-mutated diffuse grade III gliomas regraded as WHO 2016 
12 
 
grade IV). The statistical analyses were performed primarily using the WHO 2007 grade 
classification and secondarily using the updated data.  
 
Biology 
Specimens from 89 of the patients who consented to exploratory translational research were 
collected and underwent Sanger sequencing for H3F3A, Illumina 450K BeadArray 






Statistical analysis was performed using IBM SPSS Statistics for Windows, version 25 (IBM 
Corp., Armonk, N.Y., USA). Univariate relationships between nominal characteristics were 
compared using Chi-square tests. Univariate ordinal labels and numeric metrics were 
compared using Mann-Whitney (MW) and Kruskal-Wallis (KW) tests. Univariate differences 
in survival were analyzed by the Kaplan-Meier (KM) method and significance determined by 
the log-rank test in Matlab, Release 2017 (The MathWorks Inc., Natick, Massachusetts, US.). 




Of the initial 121 patients, 5 withdrew from the trial after randomization (withdrawn consent 
=4, failed to meet eligibility criteria =1). Following post-hoc pathological analysis 3 cases 
were reclassified as non-HGG tumors (oligodendroglioma grade II, n =1; anaplastic 
ganglioglioma, n =2).  The age range of the 113 patients who remained on study was 3.1 to 
17.8 years (mean 10.8 years). Sixty-seven (59%) patients were male, and 46 (41%) female. 
Following post-hoc radiological analysis, the site of tumor origin was designated as arising 
within the cerebral hemispheres (Cerebral group) in 68 (60%) patients and in a midline 
location (Midline group) in 45 (40%). A heatmap of the distribution of the epicenters can be 
seen in Figure 1. Supplementary Table ST1 provides details of the complete data set analyzed. 
Supplementary Table ST2 summarizes the demographics associated with the major mutation 
and methylation subclass entities. Following post-hoc central neuropathology review and 
integration with molecular data, the tumors were given a final histological consensus 
classification of: astrocytoma (93%, 105/113), HGG Not Otherwise Specified (NOS) (4%, 
5/113), oligoastrocytomas (3%, 3/113). After consensus review, 81% (92/113) had grade IV 
tumors and 19% (21/113) grade III tumors. 
 
 
1 - Radiological features 
The study demographics related to treatment arm, tumor grade and major mutations for the 
whole study cohort is recorded in Table 1. Table 2 details imaging features according to 
location and mutation status; Supplementary Figure SF1 details their features associated with 





Enhancement, radiological necrosis, hemorrhage, tumor volumes and ADC values 
Location 
In the Cerebral group, 40/55 (73%) showed moderate/strong tumor enhancement whilst 15/55 
(27%) had minor/no enhancement. Necrosis was present in 42/55 (76%) cases, and 
hemorrhage in 27/55 (49%) cases (all associated with necrosis). In the Midline group, 26/43 
(60%) showed moderate/strong enhancement, with minor/no enhancement in 17/43 (40%). 
Necrosis was present in 30/43 (70%), and hemorrhage in 13/43 (30%), associated with 
necrosis in 12/13. None of the above metrics were significantly different depending on 
location, nor were the ADC values, but Cerebral tumors had larger T2-weighted abnormalities 
(MW U =260.0, p <0.05), and enhancing volumes (MW U =426.0, p <0. 05). 
 
Tumor grade 
Grade IV: In 63/81 (78%) patients the tumors showed moderate/strong enhancement, with 
minor/no enhancement in 14/81 (17%) cases. Necrosis was present in 69/81 (85%) cases. 
Intratumoral hemorrhage was present in 38/81 (48%) cases.  
Grade III: Moderate/strong enhancement was present in 3/17 (18%) cases, and minor/no 
enhancement in 14/17 (82%). These enhancement patterns were significantly different to 
grade IV tumors (MW U =1,513.0, p <0.05). Although radiological tumor necrosis was 
present in 3/17 (18%), the incidence was significantly lower than grade IV tumors, χ² (1, N 
=98) =32.8, p <0.05. In 1 Midline case (right thalamic WT tumor) it was associated with 
moderate ring enhancement (Supplementary Figure SF3) and in 2 Cerebral cases with minor 
ring enhancement (Supplementary Figure SF4). In these cases, the presence of necrosis did 
not correlate with the histological grading. Intratumoral hemorrhage was present in 1/17 
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(13%) case, which was associated with necrosis, being significantly different to grade IV 
cases, χ² (1, N =99) =10.4, p <0.05. Whilst the ADC values of grade III tumors were not 
significantly different to grade IV’s, the sizes of the T2-weighted abnormalities were smaller 
(MW U =571.0, p <0.05), necrosis and cysts were more infrequent (MW U =1,513.0, p 
<0.05), and the size of the enhancing component relative to the overall tumor volume was 
smaller (MW U =709.0, p <0.05) in grade III’s. 
 
Histone Mutational status 
H3 wild type (WT): 27/35 (77%) Cerebral cases showed moderate/strong enhancement 
compared to 3/9 (33%) Midline tumors χ² (1, N =43) =5.1, p <0.05. Cerebral WT tumors also 
showed a higher incidence of necrosis (77% [27/35]) and hemorrhage (54% [19/35]) 
compared to Midline WT tumors (55% [5/9] and 22% [2/9]). 
DMG H3 K27M-mutant: These tumors were generally strongly enhancing and occurred in 
older patients (see Supplementary Figure SF5). 14/22 (64%) with preoperative imaging 
showed moderate/strong enhancement, with radiological necrosis in 15/22 (68%) and 
hemorrhage in 6/22 (27%). Compared to Midline WT tumors, H3 K27M-mutant tumors 
showed more enhancement (Mann-Whitney U =49.0, p <0.05). This was irrespective of tumor 
grade (13/22 Grade IV H3 K27M-mutant vs 3/9 Grade IV WT Midline tumors shows 
moderate/strong enhancement). In 14/23 patients with H3 K27M-mutant tumors. Tumor 
volumes and ratios, and ADC values were not significantly different between H3 K27M-
mutant and Midline WT tumors. 
H3 G34R-mutant: These tumors were generally poorly enhancing, with only 2/6 (33%) with 
pre-operative imaging available showing moderate/strong enhancement, and 4/6 (66%) 
necrosis and hemorrhage. Tumor volumes, ratios, and ADC values were not significantly 




Methylation subclass and IDH class 
The numbers of cases with defined methylation subclass and accompanying imaging were too 
few for useful evaluation except for cases with a methylation pattern similar to Pleomorphic 
Xanthoastrocytoma (PXA-like) and Diffuse IDH1-mutants, which are described below: 
PXA-like: All showed strong enhancement, 8/9 (89%) necrosis and 4/9 (44%) hemorrhage. 
Diffuse IDH1-mutant: Both cases with available imaging showed no enhancement, necrosis 
or hemorrhage. 
 
Tumor definition and perilesional edema 
 Location 
Tumor definition was comparable between Cerebral and Midline cases; 50/68 (74%) Cerebral 
tumors and 33/45 (73%) Midline tumors showed well-defined margins. Minor or absent 
perilesional edema was characteristic of Midline tumors (44/45 – 98%), with 1 case having 
moderate perilesional edema. In contrast, 46/68 (68%) Cerebral cases exhibited moderate or 
severe surrounding edema, MW U =343.0, p <0.05. 
 
Tumor grade 
In the 21 Grade III cases, no/minor perilesional edema was present in 15 (71%) whilst 6 cases 
(29%) had moderate edema (all Cerebral cases). Of the 92 grade IV patients, 51 (55%) had 
no/minor edema, and 41 moderate/severe edema (45%). Grade IV tumors were significantly 
more well-defined (72/92, 78%), χ² (1, N =113) =6.7, p <0.05, and had more moderate/severe 
edema (41/92, 45%) when compared to Grade III’s (well defined =11/21, 52%; moderate 
edema =6/21, 29%) MW U =1,374.0, p <0.05, which was also reflected in a significantly 




Histone Mutational status  
H3 WT: Perilesional edema was absent/minor in 25 (45%) patients (16 Cerebral, 9 Midline) 
and moderate/severe in 31 (55%) patients, all in the Cerebral group. 
DMG H3 K27M-mutant: Tumors were well defined in 20/23 patients; perilesional edema was 
either absent in or minor in all cases.  
Midline WT cases: Tumor definition and perilesional edema was similar to the H3 K27M-
mutant Midline tumors. 
H3 G34R-mutant: Only 2/7 (29%) cases were well-defined; 5/7 (71%) were ill-defined. 
Compared with Cerebral WT (5/47) tumors, tumor definition for H3 G34R-mutants was 
significantly different, χ² (1, N =51) =5.1, p<0.05, and they were mostly multicentric 
(discontinuous multilobar or extensively diffuse multilobar tumors) (5/7), χ² (1, N =54) =14.9, 
p <0.05 (Supplementary Figure SF6). Perilesional edema was absent/minor in 4/7, moderate 
in 2/7 and severe in 1/7 H3 G34R-mutant cases. 
 
Methylation subclass and IDH class 
PXA-like: 8/9 (89%) of PXA-like tumors were well-defined. Perilesional edema was 
absent/minor in 2/9 and moderate/severe in 7/9. All 4 patients with IDH1 mutations had 
diffuse, ill-defined tumors, with no/minor perilesional edema in 3/4. 
 
Extent of surgical resection 
Resection rates per treatment arm for the 113 patients in the study are given in Supplementary 
Table ST5, and according to tumor grade in Supplementary Table ST6. Total/near-total 
resection (NTR) occurred in 49 (43%) patients; 32 (28%) had major tumor debulking, 12 
(11%) minor debulking and 20 (18%) biopsy only. 
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The extent of total/NTR in the Cerebral group (65%) was significantly higher than in the 
Midline group (11%), MW U =529.00, p <0.05, with lower rates of minor debulking (3% vs 
22%) and biopsy (6% vs 36%), see Supplementary Figure SF7. There was a significantly 
higher total/NTR rate in Grade IV tumors (42/92 [45%]) than for Grade III tumors (7/21 
[33%]), χ² (1, N =113) =5.36, p <0.05. 
 
Leptomeningeal dissemination 
LMM dissemination occurred in 27 patients. Whole neuraxial imaging was available in 21/27 
(spinal MRI unavailable in 6/27), the imaging features of which are documented in 
Supplementary Table ST5. Supratentorial LMM was present in 16/27, infratentorial LMM in 
17/27 and spinal LMM in 15/21 (in 6 patients the spine was the only involved site). LMM 
occurred more frequently, χ² (1, N =111) =8.82, p <0.05, in patients with Midline tumors 
(17/43, 40%) than Cerebral tumors (10/68, 15%), see Figure 2. In 6/17 (35.3%) Midline cases 
with pre-operative imaging the primary lesion showed minor or no enhancement (an example 
can be seen in Supplementary Figure SF8). In contrast, the primary tumor showed strong 
enhancement in all 8 (100%) patients with LMM who had Cerebral tumors with pre-operative 
imaging available.  
All 9 Cerebral cases with LMM underwent major/GTR, however LMM occurred in 
55% (10/18) of Midline cases where there had been major/GTR, indicating that extent of 
resection did not have a substantial impact upon the incidence of LMM.  
In 11/17 of all the Midline cases with LMM, leptomeningeal disease occurred in the 
presence of stable primary tumor; in 6/17 there was concurrent local progression and distant 
leptomeningeal spread. In 5/10 of Cerebral cases LMM occurred in the presence of stable local 
disease; local progression and LMM occurred concurrently in 5/10.  In total, 16/27 (59%) 
cases displayed LMM disease in the presence of local tumor control.  
19 
 
There was no statistical difference in incidence of LMM between treatment arms, 
occurring in 15/27 (56%) patients in the RT/TMZ (15/27 – 56%) and 12/27 (44%) in the BEV 
arm. LMM occurred in 8/23 (35%) patients with an H3 K27M mutation (4 in each treatment 
arm), in 14/56 (25%) patients with WT mutations (10 in the RT/TMZ arm and 4 in the BEV 
arm), and in 1/7 patient with an H3 G34 mutation (RT/TMZ arm). Four patients with LMM 
had no tissue sample available for molecular assessment. Of the 13 Midline tumor cases with 
LMM that had molecular data available, 8/13 (62%) had H3 K27M mutations (4 in each 
treatment arm) and 5/13 (38%) WT mutations (all in the RT/TMZ arm).  
 
Pseudoprogression and pseudoresponse 
Pseudoprogression occurred in 8/111 (7%) cases (2 patients died early in the treatment and 
had no imaging), 5 in the RT/TMZ arm (for an example, see SF9), and in 3 cases in the BEV 
arm, χ² (1, N =111) =0.75, p =0.39. psPD was present in 6/68 in the Cerebral group and 2/45 
in the Midline group. In the Cerebral group, four had lobar tumors (1 with an H3 G34 
mutation, 3 with WT mutations [1 with PXA-like methylation sub-type]), and two diffuse 
multicentric tumors (1 with an H3 G34 mutation, no molecular data on the second). In the 
Midline group, 2 patients had H3F3A K27M mutations, one uni-thalamic and one a diffuse 
bi-thalamic tumor. In those patients with MGMT gene promoter status available, 5 were 
unmethylated whilst 1 was methylated (2 had no biological samples. There were no cases of 
pseudoresponse in the study cohort. 
 
2 - Outcomes measures 
Midline tumors had significantly shorter EFS (median 7.3 vs 11.4 months, log-rank p <0.05) 
and OS (median 12.7 vs 17.8 months, log-rank p <0.05) than Cerebral tumors. H3 K27M-
mutant tumors showed no distinct survival characteristics compared to WT Midline tumors 
20 
 
(Supplementary Figure SF10). Diffusely infiltrative or multilobar tumors had significantly 
shorter EFS (median 5.5 vs 11.0 months, log-rank < 0.05) and OS (median 10.8 vs 17.6 
months, log-rank < 0.05), as did those with LMM (EFS median 4.4 vs 13.4 months, log-rank 
p <0.05; OS median 9.0 vs 18.4 months, log-rank p <0.05). Well-defined tumors had 
significantly longer EFS (median 10.5 vs 8.1 months, log-rank p <0.05) and OS (median 16.5 
vs 13.4 months, log-rank p <0.05), Tumors with large (> median size) cystic and/or necrotic 
components had significantly shorter EFS (median 5.5 vs 11.2 months, log-rank p <0.05 and 
OS (median 10.1 vs 16.1 months, log-rank p <0.05) than those with small or no cysts/ necrotic 
areas. KM curves for these groups can be seen in Figure 3. There was no significant 
difference in EFS or OS related to the size of the overall abnormality, whole tumor or 
enhancement volumes, or in relation to average and minimum ADC values. Both EFS and OS 




Extent of surgical resection 
Supplementary Figure SF11 indicates the EFS and OS outcomes for Total/NTR compared 
with minor debulk, major debulk and biopsy only. Whilst there was no significant difference 
in outcome between patients undergoing major compared to minor tumor debulking (EFS log-
rank p =0.69, OS p =0.84), there was a significant difference between major debulk and 
total/NTR (EFS log-rank p <0.05; OS log-rank p <0.05), see Figure 4. There was no 
significant difference between treatment arms and type of resection, MW U =1492.00, p 
=0.27. 
Anatomical location 
Supplementary Table ST6 details the outcome for Cerebral and Midline location tumors 
according to treatment arm, with more precise locations for Cerebral cases in Supplementary 
Table ST7 and Midline in ST8.  
Tumor grade 
Supplementary Table ST9 displays the outcomes related to tumor grade. There was no 
significant difference between Grade III and Grade IV tumors (mean EFS 15.7 vs 11.8 
months, log-rank p =0.36; mean OS 19.3 vs 17.8 months, log-rank p =0.85). There was a 
significant difference in EFS between Cerebral Grade III and Grade IV (mean EFS =19.5 v 
13.8 months, log-rank p <0.05), but not in the Midline group (mean EFS =9.6 and 8.9 months, 




, there was no significant difference in outcome between the BEV and 
the RT/TMZ arms. Adjusting for location, there were no differences in either EFS (Cerebral 
RT/TMZ median EFS =14.0 v BEV 14.6 months and Midline RT/TMZ median EFS =7.9 v 
BEV 6.4 months, log-rank p =0.51) or OS (Cerebral RT/TMZ median OS =31.7 v BEV 31.4 





Outcomes for patients with LMM are provided in Supplementary Table ST10 and KM curves 
for patients with and without leptomeningeal disease are given in Supplementary Figure 
SF12. Compared to local recurrence/progression cases only, patients with LMM had 
significantly shorter EFS (mean 5.2 vs 12.5 months) and OS (median 10.7 vs 27.0 months), 





The HERBY study is one of the largest multicenter, multinational phase II randomized trials 
of pediatric HGGs undertaken. The primary outcome measures were drug safety, OS and EFS 
as defined by RANO. The trial opened in 2011, prior to the development of radiological 
response assessment criteria, the discovery of histone gene mutations
17,18
 and subsequent 
extensive genome sequencing
19,20
, and the WHO 2016 classification of a distinct entity of 
tumors defined as Diffuse Midline Gliomas with H3 K27M mutation
16
. The present study 
provides a more detailed analysis of the radiological findings following extended post-hoc 
imaging analysis. There was a 40% incidence of radiologically defined Midline tumors. 
Tissue samples for mutation and methylation subclass evaluation were available in 32/45 
(71%) of Midline tumor patients remaining on study, of whom 23/32 (72%) harbored H3 
K27M mutations; none were present in the Cerebral Group, consistent with recently reported 
studies
16,18,21,22
. In contrast to the 2016 WHO descriptor of these tumors showing diffuse 
tumoral infiltration at a microscopic scale
23
, in 78% (36/46) of cases the tumors were 
radiologically well-defined.  Although the majority of patients with H3K27 M mutations 
showed strong enhancement, a substantial minority (9/23) were classified as Grade III, of 
which 7/8 with preoperative imaging showed little or no enhancement. As the trial started 
prior to the publication of the current WHO criteria, these tumors would now be classified as 
Grade IV. Aboian et al.
24
 have previously performed a radiological comparison between H3 
K27M-mutant and other midline WT tumors, including ADC values
25
. Our findings generally 
agree with their results but for the significantly higher proportion of strongly enhancing H3 
K27M-mutants with respect to WTs in the HERBY cohort.  
The OS and EFS of the Midline tumors were significantly shorter than for the Cerebral 
Group. For both groups, patients on the BEV arm had a lower incidence of MRI contrast 
enhancement of the recurrent/progressing tumor compared to those on the RT/TMZ arm, 
24 
 
which may indicate a differential response to BEV of these tumors. The poorer outcome 
metrics of the Midline group likely reflects a combination of: 
1. The high (72%) incidence of H3 K27M-mutant tumors identified in patients with 
Midline tumors who had biological material available for analysis 
2. A significantly lower incidence of total/NTR reflecting the unfavorable surgical 
location of these tumors compared to Cerebral tumors  
3. Higher incidence of leptomeningeal dissemination. 
 
Regarding extent of tumor resection, defining tumor margins and degree of surgical 
excision, particularly with poorly or totally non-enhancing tumors, remains a radiological 
challenge. When tumors are diffuse and ill-defined the surgical margins become indistinct, 
limiting the ability to achieve a complete resection. Anatomical localization also determines 
the degree of resection possible, tumors involving midline structures being more surgically 
challenging. This is reflected by the lower proportion of total/NTR or major tumor debulking 
in Midline tumors (42%) compared with Cerebral tumors (91%). Whilst achieving total/NTR 
confers an overall survival benefit, the significant difference in OS and EFS between 
debulking (minor and major), as compared to total/NTR supports the value of near complete 
cytoreduction compared with any other form of surgery. These findings are in line with other 
studies
26–29
 but are different to those reported in the main HERBY paper
1
, where extent of 
resection was defined surgically, and suggested no significant differences debulking (minor or 
major) and total/NTR. The disagreement between the radiological and surgical criteria 
affected 19% of the patients in the HERBY study.   
Although small in number, there did not appear to be a negative outcome effect of 
Midline tumors harboring an H3 K27M mutation compared to those with WT mutations. This 
result is different to that of Karremann et al.
30
, who showed a clear poorer survival in H3 
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K27M mutants, although also including diffuse intrinsic pontine gliomas (DIPGs). In 
addition, the poor survival in the HERBY cohort of the histone WT Midline cases compared 
to that of the H3 K27M mutant group might possibly be explained by a substantially larger 
proportion of biopsies in the WT group. The radiological features and OS/EFS metrics of 
Midline tumor cases without molecular data were similar to those where H3 K27M mutations 
were present. With respect to tumor grade, there was a significant difference in OS and EFS 
between Cerebral and Midline tumors for both Grade III and Grade IV tumors, the poorer 
outcome of the Midline tumors reflected by the high proportion of H3 K27M-mutant tumors 
in this location as well as lower resection rates.  
Radiological necrosis was identified by radiological imaging in three patients that 
were histopathologically assigned as grade III tumors. In two cases that had biopsy only (one 
bi-thalamic, one a diffuse left insular tumor) this apparent contradiction may have reflected 
surgical sampling of parts of the tumor that were not radiologically necrotic, possibly 
resulting in mis-grading of these tumors. This may in turn have underestimated the difference 
in outcome metrics between Grade III and Grade IV tumors.      
Pseudoprogression was identified in 8/111 (7.1%) of cases, 5 in the RT/TMZ arm and 
3 in the BEV arm, which is lower than that reported in comparable adult HGG studies that 
report up to a 36% incidence
31
. The survival benefit conferred by exhibiting psPD, although 
not meeting statistical significance, appears to mirror that reported in some studies of adult 
GBM patients
32–34
. Leptomeningeal and/or sub ependymal dissemination occurred in 24% of 
the study population, with a higher incidence in patients with Midline tumors (40%) 
compared to Cerebral tumors (15%). In contrast, the incidence in adult HGG studies is lower; 
Parsa et al recorded an incidence of 2.3% (ependymal and distant leptomeningeal) in 1471 
patients
25
.  In a smaller study in 1994, Arita et al. found 20/157 patients with HGGs with 
antemortem (myelographic) diagnosed leptomeningeal spread, although 7 occurred in patients 
26 
 
<19 years of age
36
. Excluding patients with evidence of LMM at presentation, Dardis et al. 
identified 30 patients with LMM in a retrospective analysis of 12,477 patients
37
. The reported 
incidence of LMM is higher in pediatric HGG. Wagner et al. found a 17% incidence of LMM 
in 256 patients <20 years of age presenting with newly diagnosed HGG or DIPG identified on 
MRI
38
, a similar proportion to the HERBY study. The higher incidence of Midline tumors in 
the HERBY study with LMM mirrors the high incidence of LMM in DIPG, which share a 
high incidence of H3 K27M mutations. Buczkowic et al. found LMM in 17/44 (38.6%) 
patients with DIPG who had an autopsy
39
. It is possible that the incidence of LMM in patients 
recruited to the HERBY study would have been higher if autopsies had been undertaken in all 
non-surviving children. The presence of LMM is an important factor in the assessment of 
tumor response to therapy, which is under-represented in the RANO criteria (spinal imaging 
and exclusion of LMM is not routinely undertaken in the adult context). Post-hoc analysis 
revealed LMM at an earlier stage than detected by the study CRRC in several cases, reflecting 
the difficulty in identifying the earliest subtle features even within the context of an 
independent review process.  
In conclusion, the HERBY study confirms the phenotypically distinct entity of 
Midline tumors that harbor a high incidence of H3 K27M mutations. Radiologically these 
tumors are characterized by being well-defined with minimal or no perilesional edema in the 
vast majority of cases, and smaller tumor volumes at presentation, likely reflecting their 
central location.  Regarding outcome metrics, OS and EFS of these tumors were significantly 
shorter than that of tumors arising in the Cerebral hemispheres (apart from the small number 
with H3 G34R mutations), highlighting the importance of considering these tumors separately 
in future prospective therapeutic interventional trials of pediatric HGGs. Midline tumors 
included a subset that uniquely harbored an H3 K27M histone mutation, had a lower 
total/NTR rate (42% vs 91%) and a higher incidence of leptomeningeal dissemination (38% 
27 
 
vs 15%). The universally worse prognosis of Midline tumors for both H3K27M-mutant and 
WT histone mutants supports considering these tumors holistically when defining treatment 
paradigms, even when biological markers are not available.  
The HERBY study has emphasized the heterogeneity of molecular findings, imaging 
and response to therapy in pediatric HGGs. Incorporating leptomeningeal dissemination in 
future pediatric-focused response assessment criteria is stressed. The importance of 
determining a midline location and other related radiological characteristics of these tumors, 
which present a worse outcome than cerebral ones, should be considered when designing 
future therapeutic trials of pediatric HGGs.  
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45 (40)  
68 (60) 
    
a
Stratification factors for randomization.  
Abbreviations: RT, radiotherapy; TMZ, Temozolomide; BEV, bevacizumab; HGG, high-
grade glioma; WHO, World Health Organization. 
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Fig. 1. Location and examples of typical pediatric high-grade gliomas in the HERBY study. 
Epicenter heatmaps of Cerebral (A) and Midline (B) tumors overlaid on a standardized T1-
weighted pediatric brain. Exemplar sequences: T2-weighted, Fluid-attenuated inversion 
recovery (FLAIR), contrast enhanced T1-weighted, and apparent diffusion coefficient (ADC) 
of a Cerebral tumor (C) and a Midline tumor (D). 
 
 Fig. 2. Incidence of leptomeningeal spread in Cerebral versus Midline tumors.  
 
Fig. 3. Radiological characteristics resulting in statistically significant (p <0.05) differences in 
event-free survival (EFS) and overall survival (OS) curves: Location, multicentric, necrotic 
and/or cystic volume and well-defined. 
 
Fig. 4. Survival curves of Event Free Survival (EFS) and Overall Survival (OS) of Major 
debulk vs Total/Near Total Resection (NTR): In both cases they are signifficantly different, 
log-rank p <0.05. 
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